home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

The worlds biggest genetic experiment

  August, 22 2006 17:12
your information resource in human molecular genetics
A team of international scientific and medical experts said the success of a local three-month pilot phase, involving 3,800 participants around Manchester, meant the UK Biobank project could now be rolled out nationwide from the end of 2006.

Over the next four years, blood and urine samples will be collected from volunteers aged 40 to 69, to help us unravel the genetic foundations of common diseases, including cancer, heart disease, diabetes, dementia and joint problems.

The mapping of the human genome in 2000 opened the door to the detailed analysis of genes but experts are still grappling to understand how they interact with lifestyle and environment in terms of disease etiology.

In the long term, scientists believe the project could improve prevention, diagnosis and treatment of diseases and help to explain why certain people react differently to medications.

The 61 million pound ($115.6 million) project will be funded by the British government, the Wellcome Trust medical research charity and other sources.

Some researchers have expressed concerns about the design, size and cost of the project, but principle investigator Professor Rory Collins said he was confident it would produce valuable medical breakthroughs.

A total of around 10 million samples are expected to be collected from the half million volunteers. That genetic data will be cross-referenced against information about patients' subsequent health, obtained with their consent.

Researchers from around the world will be able to apply to UK Biobank for access to the resource but there will be strict security systems to protect participants' privacy.

Health Minister Andy Burnham said Britain was "leading the world" with the project, which would underpin the country's academic and industrial research capability.

No one organization or commercial body will have exclusive access to the data but pharmaceutical companies are expected to be able to use the results to help design new drugs and diagnostic tests.

Message posted by: Simon Chandler

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.